Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History GILD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics GILD

Max Ratio

5Y Dividend Growth

22.00 %

Consecutive Years

9 years

5Y Average Payout Ratio

760.54 %
Forward Annual Dividend Yield 2.83 %
Consecutive Years 9
Forward Annual Dividend 3.16 USD
Consistent Years 9
Dividend CAGR 3Y 2.74 %
Continuous Dividends
Dividend CAGR 5Y 4.10 %
Payout Ratio TTM 40.31 %
Dividend CAGR 10Y
Ex Dividend Date 13.06.2025

Gilead Sciences Inc

GILD
Current price
111.75 USD +0.24 USD (+0.22%)
Last closed 111.51 USD
ISIN US3755581036
Sector Healthcare
Industry Drug Manufacturers - General
Exchange NASDAQ
Capitalization 139 009 179 648 USD
Yield for 12 month +65.43 %
1Y
3Y
5Y
10Y
15Y
GILD
21.11.2021 - 28.11.2021

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California. Address: 333 Lakeside Drive, Foster City, CA, United States, 94404

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

116.77 USD

P/E Ratio

23.48

Dividend Yield

2.83 %

Financials GILD

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures GILD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+28 754 000 000 USD

Last Year

+27 116 000 000 USD

Current Quarter

+6 667 000 000 USD

Last Quarter

+7 569 000 000 USD

Current Year

+22 503 000 000 USD

Last Year

+27 116 000 000 USD

Current Quarter

+5 127 000 000 USD

Last Quarter

+5 988 000 000 USD
EBITDA 13 724 000 256 USD
Operating Margin TTM 38.49 %
Price to Earnings 23.48
Return On Assets TTM 12.14 %
PEG Ratio 0.23
Return On Equity TTM 32.65 %
Wall Street Target Price 116.77 USD
Revenue TTM 28 735 000 576 USD
Book Value 15.39 USD
Revenue Per Share TTM
Dividend Share 3.10 USD
Quarterly Revenue Growth YOY -0.30 %
Dividend Yield 2.83 %
Gross Profit TTM 22 496 000 000 USD
Earnings per share 4.76 USD
Diluted Eps TTM 4.76 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY 24.80 %
Profit Margin 20.76 %

Stock Valuation GILD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 23.48
Forward PE 14.12
Enterprise Value Revenue 5.43
Price Sales TTM 4.84
Enterprise Value EBITDA 14.75
Price Book MRQ 7.25

Technical Indicators GILD

For 52 Weeks

64.27 USD 118.28 USD
50 Day MA 106.80 USD
Shares Short Prior Month 20 937 020
200 Day MA 99.03 USD
Short Ratio 2.85
Shares Short 22 993 007
Short Percent 1.85 %